The Federal Circuit’s recent ruling in Acetris Health LLC v. United States, No. 18-2399 (Fed. Cir. 2020), held that pharmaceuticals with an active ingredient from India but manufactured into final form in the US qualify as “US made” for purposes of federal procurement law. The decision, if not successfully challenged, could have broad-ranging implications that extend beyond the pharmaceutical industry to any government contractor with international supply chains. Acetris also raises important questions about how federal agencies will implement the court’s guidance. Join us for a webinar focusing on what this new case may mean for your products and business processes.